观点交锋:哌拉西林-他唑巴坦是否应用于治疗产超广谱β-内酰胺酶细菌感染
本文以观点交锋形式讨论哌拉西林-他唑巴坦(PTZ)治疗产超广谱β-内酰胺酶(ESBL)革兰阴性菌感染的利弊。正方Schuetz主张在特定条件下可用PTZ,反方Reyes与Tamma持反对观点,并探讨实验室如何报告BLBLI药敏结果以配合抗菌药物管理。
要点
- PTZ对部分ESBL菌株仍保持活性,但疗效可能降低。
- 菌株MIC、感染部位与严重程度、耐药机制类型影响BLBLI选择。
- 快速诊断可检出CTX-M等ESBL机制,实验室报告方式需结合抗菌药物管理。
核心结论
- PTZ治疗ESBL-GNR感染的利弊存在争议,需综合菌株MIC、感染部位与严重程度、耐药机制类型及抗菌药物管理原则决策。
研究设计与样本
- 本文为观点交锋(Point-Counterpoint)综述,由Schuetz陈述正方观点,Reyes与Tamma陈述反方观点。
主要发现
- PTZ是常用经验性覆盖革兰阴性菌的药物,对大部分ESBL-GNR菌株仍保持活性。
- 部分数据提示PTZ对ESBL的疗效降低。
- 快速诊断可检出CTX-M型或其他ESBL耐药机制,使该问题持续受关注。
临床怎么用
- 临床选择BLBLI时应考虑分离株MIC、感染部位与严重程度及耐药机制类型。
- 实验室报告BLBLI对ESBL菌株的药敏结果时应结合抗菌药物管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTIONBeta-lactam/beta-lactamase inhibitor combination antimicrobials (BLBLIs) are among the most controversial classes of antibiotic agents available for the treatment of infections caused by extended-spectrum-beta-lactamase (ESBL)-producing Gram-negative bacteria (ESBL-GNR). Piperacillin-tazobactam (PTZ) is one of the most frequently utilized antibiotic agents for empirical Gram-negative bacterial coverage and remains active against a large proportion of ESBL-GNR strains. Furthermore, good antimicrobial stewardship practices encourage the use of carbapenem-sparing treatment regimens for infections due to ESBL-GNR. As rapid diagnostics are increasingly used in the clinical microbiology laboratory and have the capability of detecting CTX-M type or other ESBL resistance mechanisms, this issue continues to be pertinent. Some data imply reduced efficacy of PTZ against ESBLs. Several factors may affect a clinician's choice to use BLBLIs, including the isolate's MIC, the site and severity of infection, and the type of resistance mechanism. These factors are explored in this review of the pros and cons of BLBLI treatment of invasive infections due to ESBL-producing bacteria, as well as how laboratories should report results for BLBLIs for these organisms as they relate to antimicrobial stewardship. In this Point-Counterpoint, Audrey Schuetz provides the pro point of view and Sergio Reyes and Pranita Tamma provide the con, counterpoint view.
引用
- Schuetz AN, Reyes S, Tamma PD, et al. Point-Counterpoint: Piperacillin-Tazobactam Should Be Used To Treat Infections with Extended-Spectrum-Beta-Lactamase-Positive Organisms. J Clin Microbiol. 2018. PMID: 29237787. doi:10.1128/JCM.01917-17
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。